JHU scientists have developed a polyclonal antibody to the NR1 Subunit of the N-Methyl-D-aspartate (NMDA) Receptor.
Looking for Partners:
This technology encompasses an antibody specific for the NR1 Subunit of the NMDA Receptor. It has the potential to be commercialized as a biomarker for therapeutic, prophylactic or diagnostic use.